TRESUVI 5mg / ml infusion solution medication leaflet

B01AC21 treprostinil • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin

Treprostinil is a synthetic analog of prostacyclin used in the treatment of pulmonary arterial hypertension (PAH). It works by dilating blood vessels in the lungs and reducing pulmonary vascular resistance, thereby improving blood flow and exercise capacity in patients.

Treprostinil can be administered as an intravenous, subcutaneous, inhaled infusion, or oral tablets, depending on the severity of the disease and patient preferences. It is commonly used to alleviate symptoms such as shortness of breath, fatigue, and chest pain associated with PAH.

Common side effects include headache, nausea, diarrhea, pain at the injection site (for subcutaneous administration), and facial flushing. Careful monitoring is essential for dose adjustment and prevention of complications.

Treprostinil is an essential medication in managing pulmonary arterial hypertension, helping to improve quality of life and extend survival in patients.

General data about TRESUVI 5mg / ml

Substance: treprostinil

Date of last drug list: 01-06-2025

Commercial code: W66881001

Concentration: 5mg / ml

Pharmaceutical form: infusion solution

Quantity: 1

Product type: generic

Price: 12051.62 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: AMOMED PHARMA GMBH - AUSTRIA

Holder: AMOMED PHARMA GMBH - AUSTRIA

Number: 12563/2019/01

Shelf life: 3 years;after the first opening-30 days la 30°C

Concentrations available for treprostinil

10mg/ml, 1mg/ml, 2.5mg/ml, 5mg/ml

Compensation lists for TRESUVI 5mg / ml AMOMED

NHP 6.3 (C2) - Pulmonary hypertension

Price

Copayment

Patient

12051.62 RON

12051.62 RON

0.00 RON